Articles related to TARGETED THERAPIES

Researchers have identified insufficient activation of the aryl hydrocarbon receptor (AHR) pathway as a key driver in lupus pathogenesis, offering a new target for therapeutic intervention.

Careful management with endocrinology expertise is crucial when considering radioligand therapy for pheochromocytomas and paragangliomas to avoid potentially life-threatening catecholamine crises.

The TROPiCs-04 trial results challenge the current treatment landscape for metastatic urothelial carcinoma, highlighting the need for new strategies post-relapse and the importance of next-generation sequencing in patient selection.

Pirtobrutinib offers a new line of therapy for CLL and SLL patients who have progressed after covalent BTK inhibitors and venetoclax, with a significant overall response rate and manageable adverse events.

Interim results from J&J’s Phase I study of JNJ-6420 highlight both promising efficacy in prostate cancer treatment and serious safety concerns, with 60% of patients experiencing severe adverse events.

Menin inhibitors, targeting the menin-KMT2A interaction, have demonstrated significant response rates in treating specific genotypes of AML and ALL, offering a new avenue for personalized leukemia therapy.